期刊文献+

糖皮质激素对狼疮性肾炎患者肾内B淋巴细胞刺激因子的影响 被引量:9

The effect of glucocorticoid on the intrarenal expression of B lymphocyte stimulator in lupus nephritis patients
原文传递
导出
摘要 目的探讨糖皮质激素(GC)对狼疮性肾炎(LN)患者血清及肾内B淋巴细胞刺激因子(BlyS)的影响。方法用ELISA法和免疫组化法检测LN患者与正常对照者的血清和肾内BlyS的表达水平。结果 LN患者血清及肾内BlyS的表达水平显著高于正常对照者(P<0.001);GC治疗>2周组的LN患者肾内BlyS的表达水平及系统性红斑狼疮疾病活动性指数(SLEDAI)评分较未治疗组显著减少(P分别为0.012和0.005)。结论 GC减轻LN患者疾病活动性的作用可能与其降低肾内BlyS水平有关。 Objective To investigate the effect of glucocorticoid(GC) on the serum and intrarenal expression of B lymphocyte stimulator(BlyS) in patients with lupus nephritis(LN).Methods The serum and intrarenal expression of BlyS was respectively detected by ELISA and immunohistochemistry in LN patients and normal controls.Results The serum concentration and intrarenal production of BlyS in LN patients were significantly higher than that in normal controls(P〈0.001).The intrarenal production of BlyS and the serum SLEDAI scores in LN patients that have received GC therapy more than 2 weeks were obviously lower than those in LN patients that haven′t received any treatment(P=0.012,0.005).Conclusion The effect of GC therapy on disease activity in LN patients may associate with the decreasing expression level of intrarenal BlyS.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第8期572-574,共3页 The Chinese Journal of Clinical Pharmacology
关键词 系统性红斑狼疮 糖皮质激素 B淋巴细胞刺激因子 狼疮性肾炎 systemic lupus nephritis glucocorticoid B lymphocyte stimu-lator lupus nephritis
  • 相关文献

参考文献9

  • 1Moore PA, Belvedere O, Orr A, et al. BlyS:member of the tumor necrosis family and B lymphocyte stimulator[ J]. Science, 1999 ;285: 260 - 263. 被引量:1
  • 2Bombardier C, Gladman DD, Urowiz MB, et al. Derivation on the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE [ J]. Arthritis Rheum, 1992;35:630 - 640. 被引量:1
  • 3Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia autoim- mune disease in TALL- 1 transgenetic mice[ J]. Proc Natl Acad Sci USA, 2000 ;97:3370 - 3375. 被引量:1
  • 4Ramanujam M, Davidson A. BAFF blockade for systemic lupus ery- thematosus :will the promise be fufilled? [ J 1. lmmunol Rev, 2008; 223 : 156 - 174. 被引量:1
  • 5徐亮,李志,张军,陆进明.血清B淋巴细胞刺激因子在系统性红斑狼疮中的意义[J].中华风湿病学杂志,2007,11(7):417-419. 被引量:4
  • 6Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti - B - lymphocyte stimulator (BlyS) monoclonal antibody:a phase I trail in patients with systemic lupus erythematosus[ J. Arthritis Res Ther, 2008 ; 10 : R109. 被引量:1
  • 7Wallance DJ, Stohl W, Furie RA, et al. A phase II, randomized, double - blind, placebo - controlled, dose - ranging study of beli- mumab in patients with active systemic lupus erythematosus[ J]. Ar- thritis Rheum, 2009 ;61 : 1168 - 1178. 被引量:1
  • 8Furie R, Petri M, Zamani O, et al. A phase III, randomized, place- bo - controlled study of belimumab, a monoclonal antibody that in- hibits B lymphocyte stimulator, in patients with systemic lupus ery- thematosus[J]. Arthritis Rheum, 2011 ;12:3918 -3930. 被引量:1
  • 9王敏莉,李晓峰,张丽香,秦岭,罗永坚,梅元武,李吕力.糖皮质激素治疗对重症肌无力患者BAFF和IL-6水平的影响[J].中国临床新医学,2011,4(2):107-110. 被引量:10

二级参考文献21

  • 1李柱一,许贤豪,刘建军,张华.第八届全国神经免疫会议纪要[J].中华神经科杂志,2005,38(2):128-128. 被引量:14
  • 2王秀云,许贤豪,孙宏,韩雄,张华,国红.重症肌无力病人的临床绝对评分法和相对评分法[J].中华神经科杂志,1997,30(2):87-90. 被引量:241
  • 3Anlar B, Senbil N, Kose G, et al. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years[ J]. Neuromuscul Disord ,2005,15 (5) :355 -357. 被引量:1
  • 4Mocehegiani E, Giacconi R, Muzzioli M, et al. Different age-related effects of thymectomy in myasthenia gravis: role of thymoma, zinc, thymulin, IL-2 and IL-6 [ J ]. Mech Ageing Dev, 2000,117 ( 1-3 ) : 79-91. 被引量:1
  • 5Sassano P, Paparo F, Ramiefi V, et al. Interleukine-6 (IL-6) may be a link between myasthenia gravis and myoepithelioma of the parotid gland[ J]. Med Hypotheses ,2007, 68 (2) :314 - 317. 被引量:1
  • 6Vieweg J, Jackson A. Modulation of antitumor responses by dendritic cells [ J ]. Springer Semin Immunopathol,2005,26 (3) :329 - 341. 被引量:1
  • 7Shimizu K, Thomas EK, Giedlin M, et al. Enhancement of tumor lysate and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein [ J ]. Cancer Res, 2001,61 ( 6 ) :2618 - 2624. 被引量:1
  • 8Shan X, Chen L, Cao M,et al. Effects of human soluble BAFF synthesized in Escherichia coli on CD4 + and CD8+ T lymphecytes as well as NK cells in mice[J]. Physiol Res,2006,55(3) :301 -307. 被引量:1
  • 9Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders[J]. Nat Clin Pract Neurol,2008,4(I0) :557 -567. 被引量:1
  • 10Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocyte disorders along with autoimmune manifestations. J Exp Med, 1999, 190: 1697-1710. 被引量:1

共引文献12

同被引文献107

  • 1吴哲,杨贺,李彦科.狼疮性肾炎的治疗进展[J].实用药物与临床,2006,9(4):257-258. 被引量:5
  • 2陈秋霞,史建强,李常兴,周斌,覃冬梅,吴铁,吴志华.补骨胶囊预防糖皮质激素所致系统性红斑狼疮患者骨质疏松或骨量减少的研究[J].中华皮肤科杂志,2006,39(10):584-586. 被引量:2
  • 3Michael W, Matthew J, David J, et al. Mycophenolate mofetil for in- duction therapy of lupusnephritis : a systematic review and meta anal- ysis [ J ]. Clin J Am Soc Nephro,2007, ( 2 ) :968 - 975. 被引量:1
  • 4Kamanamool N, McEvoy M, Attia J, et al. Efficacy and Adverse E- vents of Mycophenolate Mofetil Versus Cyclophosphamide for Induc- tion Therapy of Lupus Nephritis : Systematic Review and Meta-Analy- sis[J]. Medicine,2010,89(4) :227 -235. 被引量:1
  • 5Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclo- phosphamide delays the progression of chronic lesions more effective- ly than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis[ J ]. Arthritis and Rheuma- tism,2007,56 ( 3 ) :924 - 937. 被引量:1
  • 6Zhang FS,Nie YK,Jin XM, et al. The efficacy and safety of lefluno- mide therapy in lupus nephritis by repeat kidney biopsy [ J ]. Rheu- matolInt, 2009,29 ( 11 ) : 1331 - 1335. 被引量:1
  • 7Miyasaka N, Kawai S, Hashimoto H, et al. Efficacy and safety of ta- crolimus for lupus nephritis:a placebo-controlled double-blind multi- center study [ J ]. Modern rheumatology ,2009,19 (6) :606 - 615. 被引量:1
  • 8Chen W,Tang X, Liu Q, Chen W, et al. Short-term outcomes of in- duction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis : A muhicenter randomized clinical trial [ J ]. Am J Kidney Dis ,2011,57 (2) :235 - 244. 被引量:1
  • 9Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analy- sis of the use of B cell depletion therapy in systemic lupus erythema- tosus at University College London Hospital: the first fifty patients [ J]. Arthritis Rheum,2009,61 (4) :482 - 487. 被引量:1
  • 10Elie C, Brocheriou I, Knebelmann B, et al. Rituximab in Severe Lu- pus Nephritis:Early B-Cell Depletion Affects Long-Term Renal Out- come [ J ]. CJASN .2009.4 ( 3 ) : 579 - 587. 被引量:1

引证文献9

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部